Health Care [ 4/12 ] | Pharmaceuticals [ 26/74 ]
NYSE | Common Stock
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry.
Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks.
It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians.
Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 24, 25 | 0.14 Increased by +75.00% | 0.15 Decreased by -5.79% |
| Nov 7, 24 | 0.13 Decreased by -27.78% | 0.12 Increased by +8.33% |
| Aug 8, 24 | 0.30 Increased by +66.67% | 0.24 Increased by +25.00% |
| May 8, 24 | 0.34 Decreased by -24.44% | 0.26 Increased by +30.77% |
| Feb 26, 24 | 0.08 Decreased by -57.89% | 0.11 Decreased by -27.27% |
| Nov 7, 23 | 0.18 Decreased by -10.00% | 0.12 Increased by +50.00% |
| Aug 7, 23 | 0.18 Decreased by -50.00% | 0.05 Increased by +260.00% |
| May 9, 23 | 0.45 Increased by +25.00% | 0.29 Increased by +55.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 1.02 B Decreased by -1.45% | -8.00 M Increased by +94.33% | Decreased by -0.78% Increased by +94.24% |
| Sep 30, 24 | 1.03 B Decreased by -3.56% | 364.00 M Increased by +133.21% | Increased by +35.34% Increased by +134.44% |
| Jun 30, 24 | 1.18 B Increased by +12.02% | -50.00 M Increased by +48.45% | Decreased by -4.22% Increased by +53.98% |
| Mar 31, 24 | 1.21 B Decreased by -4.14% | 32.00 M Decreased by -68.93% | Increased by +2.66% Decreased by -67.59% |
| Dec 31, 23 | 1.03 B Increased by +4.76% | -141.00 M Decreased by -161.11% | Decreased by -13.62% Decreased by -149.25% |
| Sep 30, 23 | 1.07 B Increased by +3.89% | -1.10 B Decreased by -2.14 K% | Decreased by -102.62% Decreased by -2.05 K% |
| Jun 30, 23 | 1.06 B Decreased by -10.20% | -97.00 M Decreased by -340.91% | Decreased by -9.18% Decreased by -390.96% |
| Mar 31, 23 | 1.26 B Increased by +2.61% | 103.00 M Increased by +101.96% | Increased by +8.19% Increased by +96.82% |